Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

San Francsiscan liver specialist 89bio (Nasdaq: ETNB) has secured $250 million through a public stock offering, following a ...

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...

Inc. (NASDAQ:ETNB – Get Free Report) was the recipient of some unusual options trading on Monday. Traders acquired 2,228 call options on the company. This is an increase of 346% compared to the ...

Inc. (NASDAQ:ETNB – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven analysts that ...

SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...

(NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of ...

For MASH developers, a race for cash: Akero Therapeutics aims to raise $300 million in an offering ...

SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...